March 24, 2020
Novavax with positive score in Phase 3 of NanoFlu
Novavax published positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.